Liver function may change how olomorasib works – new study investigates

NCT ID NCT06719128

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 study looked at how olomorasib, an oral drug, enters the bloodstream and leaves the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. 46 participants received a single dose. The goal is to understand if liver function affects drug levels, which could guide future dosing. Safety was also monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olomorasib (also called LY3537982), an oral drug
What this could lead to: If successful, this study could help doctors decide the right dose of olomorasib for patients with liver problems.
What could go wrong: This is an early, small study focused on drug levels, not on treating a disease. Results may not apply to real-world patients or predict safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver disorder liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY HEPATIC INSUFFICIENCY

Contacts and locations

Locations

American Research Corporation at Texas Liver Institute

San Antonio, Texas, 78215, United States
Clinical Pharmacology of Miami

Miami, Florida, 33014, United States
Orange County Research Center

Lake Forest, California, 92630, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.